• 1
    Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis. 2010; 16: 15981619.
  • 2
    Chitturi S, Farrell GC, Hashimoto E, et al. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. J Gastroenterol Hepatol. 2007; 22: 778787.
  • 3
    Steed H, Walsh S, Reynolds N. A brief report of the epidemiology of obesity in the inflammatory bowel disease population of Tayside, Scotland. Obesity Facts. 2009; 2: 370372.
  • 4
    Geerling BJ, Badart-Smook A, Stockbrugger RW, et al. Comprehensive nutritional status in patients with long-standing Crohn disease currently in remission. Am J Clin Nutr. 1998; 67: 919926.
  • 5
    Long MD, Crandall WV, Leibowitz IH, et al. Prevalence and epidemiology of overweight and obesity in children with inflammatory bowel disease. Inflamm Bowel Dis. 2010 [Epub ahead of print].
  • 6
    National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. Obes Res. 1998; 6( suppl 2): 51S209S.
  • 7
    Dutt MK, Davies DR, Grace RH, et al. Sampling variability of liver biopsy in inflammatory bowel disease. Arch Pathol Lab Med. 1983; 107: 451452.
  • 8
    Perrett AD, Higgins G, Johnston HH, et al. The liver in ulcerative colitis. Q J Med. 1971; 40: 211238.
  • 9
    Perrett AD, Higgins G, Johnston HH, et al. The liver in Crohn's disease. Q J Med. 1971; 40: 187209.
  • 10
    Wee A, Ludwig J. Pericholangitis in chronic ulcerative colitis: primary sclerosing cholangitis of the small bile ducts? Ann Intern Med. 1985; 102: 581587.
  • 11
    Broome U, Glaumann H, Hultcrantz R. Liver histology and follow up of 68 patients with ulcerative colitis and normal liver function tests. Gut. 1990; 31: 468472.
  • 12
    Bargiggia S, Maconi G, Elli M, et al. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. J Clin Gastroenterol. 2003; 36: 417420.
  • 13
    Gisbert JP, Luna M, González-Lama Y, et al. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis. 2007; 13: 11061114.
  • 14
    Mendes FD, Levy C, Enders FB, et al. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol. 2007; 102: 344350.
    Direct Link:
  • 15
    Thomas C. Ulceration of the colon with a much enlarged fatty liver. Trans Pathol Soc Philadelphia. 1873: 8788.
  • 16
    Logan AH. Chronic ulcerative colitis: a review of 117 cases. Northwest Med. 1919; 18.
  • 17
    Ross JR, Swarts JM. Hepatic dysfunction and cirrhosis in chronic ulcerative colitis. Gastroenterology. 1948; 10: 8195.
  • 18
    Pollard HM, Block M. Association of hepatic insufficiency with chronic ulcerative colitis. Arch Intern Med (Chicago). 1948; 82: 159174.
  • 19
    Warren S, Sommers SC. Pathogenesis of ulcerative colitis. Am J Pathol. 1949; 25: 657679.
  • 20
    Dyson FL. Liver damage in ulcerative colitis. Br Med J. 1950; 1: 13011302.
  • 21
    Jones GW, Baggenstoss AH, Bargen JA. Hepatic lesions and dysfunction associated with chronic ulcerative colitis. Am J Med Sci. 1951; 221: 279286.
  • 22
    Kimmelstiel P, Large HL Jr, Verner HD. Liver damage in ulcerative colitis. Am J Pathol. 1952; 28: 259289.
  • 23
    Parker RG, Kendall EJ. The liver in ulcerative colitis. Br Med J. 1954; 2: 10301032.
  • 24
    Chapin LE, Scudamore HH, Baggenstoss AH, et al. Regional enteritis: associated visceral changes. Gastroenterology. 1956; 30: 404415.
  • 25
    Monto AS. The liver in ulcerative disease of the intestinal tract: functional and anatomic changes. Ann Intern Med. 1959; 50: 13851394.
  • 26
    Palmer WL, Kirsner JB, Goldgraber MB, et al. Disease of the Liver in Chronic Ulcerative Colitis. Am J Med. 1964; 36: 856866.
  • 27
    De Dombal FT, Goldie W, Watts JM, et al. Hepatic histological changes in ulcerative colitis. A series of 58 consecutive operative liver biopsies. Scand J Gastroenterol. 1966; 1: 220227.
  • 28
    Dordal E, Glagov S, Kirsner JB. Hepatic lesions in chronic inflammatory bowel disease. I. Clinical correlations with liver biopsy diagnoses in 103 patients. Gastroenterology. 1967; 52: 239253.
  • 29
    Eade MN. Liver disease in ulcerative colitis. I. Analysis of operative liver biopsy in 138 consecutive patients having colectomy. Ann Intern Med. 1970; 72: 475487.
  • 30
    Eade MN, Cooke WT, Brooke BN, et al. Liver disease in Crohn's colitis. A study of 21 consecutive patients having colectomy. Ann Intern Med. 1971; 74: 518528.
  • 31
    Mattila J, Aitola P, Matikainen M. Liver lesions found at colectomy in ulcerative colitis: correlation between histological findings and biochemical parameters. J Clin Pathol. 1994; 47: 10191021.
  • 32
    Scalone O, Bonaventure C, Pasquier D, et al. [Should liver biopsy be systematic during surgery for ulcerative colitis?] Gastroenterol Clin Biol. 2003; 27: 9499.
  • 33
    de Fazio C, Torgano G, de Franchis R, et al. Detection of liver involvement in inflammatory bowel disease by abdominal ultrasound scan. Int J Clin Lab Res. 1992; 21: 314317.
  • 34
    Riegler G, D'Inca R, Sturniolo GC, et al. Hepatobiliary alterations in patients with inflammatory bowel disease: a multicenter study. Caprilli & Gruppo Italiano Studio Colon-Retto. Scand J Gastroenterol. 1998; 33: 9398.
  • 35
    Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70: 439444.
  • 36
    Barton JR, Ferguson A. Clinical features, morbidity and mortality of Scottish children with inflammatory bowel disease. Q J Med. 1990; 75: 423439.
  • 37
    Ferguson A, Sedgwick DM. Juvenile onset inflammatory bowel disease: height and body mass index in adult life. BMJ. 1994; 308: 12591263.
  • 38
    Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999–2008. JAMA. 2010; 303: 235241.
  • 39
    Rogler G. Gastrointestinal and liver adverse effects of drugs used for treating IBD. Best Pract Res Clin Gastroenterol. 2010; 24: 157165.
  • 40
    Dourakis SP, Sevastianos VA, Kaliopi P. Acute severe steatohepatitis related to prednisolone therapy. Am J Gastroenterol. 2002; 97: 10741075.
    Direct Link:
  • 41
    Candelli M, Nista EC, Pignataro G, et al. Steatohepatitis during methylprednisolone therapy for ulcerative colitis exacerbation. J Intern Med. 2003; 253: 391392.
  • 42
    Goodman TA, Polisson RP. Methotrexate: adverse reactions and major toxicities. Rheum Dis Clin North Am. 1994; 20: 513528.
  • 43
    Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol. 1996; 91: 423433.
  • 44
    Cuffari C, Theoret Y, Latour S, et al. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut. 1996; 39: 401406.
  • 45
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 15411549.
  • 46
    Coffin CS, Fraser HF, Panaccione R, et al. Liver diseases associated with anti-tumor necrosis factor-alpha (TNF-alpha) use for inflammatory bowel disease. Inflamm Bowel Dis. 2011; 17: 479484.
  • 47
    Argiles JM, Lopez-Soriano J, Busquets S, et al. Journey from cachexia to obesity by TNF. FASEB J. 1997; 11: 743751.
  • 48
    Briot K. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor treatment. Ann Rheumatic Dis. 2005; 64: 11371140.
  • 49
    Gisondi P, Cotena C, Tessari G, et al. Anti-tumour necrosis factor-α therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol. 2008; 22: 341344.
  • 50
    Saraceno R, Schipani C, Mazzotta A, et al. Effect of anti-tumor necrosis factor-α therapies on body mass index in patients with psoriasis. Pharmacol Res. 2008; 57: 290295.
  • 51
    Esposito M, Mazzotta A, Saraceno R, et al. Influence and variation of the body mass index in patients treated with etanercept for plaque-type psoriasis. Int J Immunopathol Pharmacol. 2009; 22: 219225.
  • 52
    Franchimont D. Impact of infliximab on serum leptin levels in patients with Crohn's disease. J Clin Endocrinol Metab. 2005; 90: 35103516.
  • 53
    Isaacs K. Infliximab therapy is associated with unexpected weight gain in patients with Crohn's disease as compared to those with rheumatoid arthritis. Chapel Hill, NC: University of North Carolina; 2010.
  • 54
    Gonzalez-Gay M. Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis. Clin Exp Rheumatol. 2009; 27: 222228.
  • 55
    Barbuio R, Milanski M, Bertolo MB, et al. Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. J Endocrinol. 2007; 194: 539550.
  • 56
    Koca SS, Bahcecioglu IH, Poyrazoglu OK, et al. The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. Inflammation. 2008; 31: 9198.
  • 57
    Satapathy SK, Garg S, Chauhan R, et al. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2004; 99: 19461952.
    Direct Link:
  • 58
    Schramm C, Schneider A, Marx A, et al. Adalimumab could suppress the activity of non alcoholic steatohepatitis (NASH). Z Gastroenterol. 2008; 46: 13691371.
  • 59
    Blain A, Cattan S, Beaugerie L, et al. Crohn's disease clinical course and severity in obese patients. Clin Nutr. 2002; 21: 5157.
  • 60
    Hass DJ, Brensinger CM, Lewis JD, et al. The impact of increased body mass index on the clinical course of Crohn's disease. Clin Gastroenterol Hepatol. 2006; 4: 482488.
  • 61
    Kiran RP, Remzi FH, Fazio VW, et al. Complications and functional results after ileoanal pouch formation in obese patients. J Gastrointest Surg. 2008; 12: 668674.
  • 62
    Kleckner MS Jr, Stauffer MH, Bargen JA, et al. Hepatic lesions in the living patient with chronic ulcerative colitis as demonstrated by needle biopsy. Gastroenterology. 1952; 22: 1333.